BOSTON, MA – December 2, 2014 – EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced the launch of its first product, Infimab (BOW015), the first infliximab biosimilar in India.

Infimab, a Remicade (infliximab) biosimilar, is being launched in cooperation with EPIRUS’ commercialization partner Ranbaxy Laboratories Limited (Ranbaxy). Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai. Remicade is currently marketed globally for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.